CYP19A1 and anemia (phenotype): Interestingly, among several kinds of adverse events, patients prioritized anemia and pneumonitis, which were two most common grade 3 or 4 adverse events from aromatase inhibitor plus mTOR inhibitor (Dhillon 2013).